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Abstract
Background: ABILHAND, a manual ability patient-reported outcome instrument originally developed
for stroke patients, has been used in multiple sclerosis clinical trials; however, psychometric analyses
indicated the measure’s limited measurement range and precision in higher-functioning multiple sclerosis patients.
Objective: The purpose of this study was to identify candidate items to expand the measurement range
of the ABILHAND-56, thus improving its ability to detect differences in manual ability in higherfunctioning multiple sclerosis patients.
Methods: A step-wise mixed methods design strategy was used, comprising two waves of patient
interviews, a combination of qualitative (concept elicitation and cognitive debriefing) and quantitative
(Rasch measurement theory) analytic techniques, and consultation interviews with three clinical neurologists specializing in multiple sclerosis.
Results: Original ABILHAND was well understood in this context of use. Eighty-two new manual
ability concepts were identified. Draft supplementary items were generated and refined with patient and
neurologist input. Rasch measurement theory psychometric analysis indicated supplementary items
improved targeting to higher-functioning multiple sclerosis patients and measurement precision. The
final pool of Early Multiple Sclerosis Manual Ability items comprises 20 items.
Conclusion: The synthesis of qualitative and quantitative methods used in this study improves the
ABILHAND content validity to more effectively identify manual ability changes in early multiple
sclerosis and potentially help determine treatment effect in higher-functioning patients in clinical trials.
Keywords: Manual ability, multiple sclerosis, ABILHAND, patient-reported outcomes, Rasch measurement theory
Date received: 31 October 2017; Revised received 26 March 2018; accepted: 13 April 2018

Introduction
In addition to walking disability, cognitive problems, depression, and fatigue, manual disability is
a prominent problem for many people with multiple
sclerosis (MS)1–4 that affects the ability to perform
essential activities of daily living efficiently and
independently.1,5 Manual disability is common2–4,6
even in the early or mild stages of the disease, with

up to 60% of patients reporting symptoms in the
first year post-diagnosis.2 Therefore, change in
manual ability is an important aspect to monitor in
clinical practice for disease progression or therapeutic effect. Traditionally, in clinical trials, manual
ability has been assessed using performance outcome measures, such as the Nine-Hole Peg Test
(9HPT).7,8 These assessments, although practical
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for use in clinical settings, are not by themselves
informative about the daily life impact of MS (and
potential treatment benefit) on patients’ manual ability. Therefore, more robust patient-reported outcomes (PROs) of manual ability are needed for
pivotal clinical trials and in the usual care setting
to assess treatment benefit from the patients’
perspective.

Materials and Methods

ABILHAND is a PRO instrument originally developed to assess manual disability in stroke9 but has
recently been used in clinical trials for MS.10–12 It is
essential to evaluate the extent to which any PRO
instrument provides valid measurement, and appropriately reflects the patient experience in any new
context of use.13,14 This may be achieved through
the discipline of psychometrics15 where three paradigms exist: traditional psychometrics based on classical test theory (CTT),16 and modern psychometrics
including Rasch measurement theory (RMT)17,18
and item response theory (IRT). A previous CTT
study of ABILHAND-23 in MS suggested adequate
reliability and validity.19 However, subsequent RMT
and
evaluations
of
ABILHAND-2319,20
20
ABILHAND-56 indicated limited measurement
range and precision (i.e., increased error associated
with measurement) in MS patients with Expanded
Disability Status Scale (EDSS) levels between 0–2,
which impact ABILHAND’s ability to detect differences in manual ability in higher-functioning MS
patients. Additional item fit analyses further suggested that there is probably more than one clinical
concept related to manual ability underlying the
scale; these concepts are “fine motor” (dexterity)
and “power.”20

Mixed methods design is broadly defined as the combination and comparison of multiple data sources,
data collection, analytical procedures, or research
methods.21 In psychometric research, mixed methods
specifically refers to the synthesis of qualitative and
quantitative methods to identify, define and operationalize PRO instruments as measures of a given
concept of interest in a specific context of use.14

Given these limitations, the goal of the study presented here was to troubleshoot the ABILHAND-56
to increase its applicability to the broadest possible
population of patients with MS. As ABILHAND-56
is used on an ongoing basis in a specific drug development program, addressing ABILHAND’s measurement limitations in higher-functioning MS
patients is important to improve measurement
range, precision, and potential to detect treatment
effect, and subsequently confirm the item clarity
and relevance in MS. In this multi-phase, mixed
methods study, we aimed to build on previous
work by identifying additional candidate items to
build on the two clinical concepts underpinning the
ABILHAND-56, and thus to improve its ability to
detect differences in manual ability in higher-functioning MS patients.

2

Study Design Overview
We used a step-wise mixed methods design strategy
comprising two waves of patient interviews, a combination of qualitative and quantitative analytic techniques, and consultation interviews with three clinical
neurologists specializing in MS (see Figure 1).

Study Population and Recruitment Process
Institutional review board approval was obtained,
and written informed consent was provided by all
study participants. Early relapsing–remitting MS
(RRMS) patients were recruited through the study
sponsor’s patient services department and through
a social media site for MS patients. Patients were
eligible to participate if they were diagnosed with
RRMS within the last two years and had a Patient
Determined Disease Steps (PDDS)22 score of 0–1
(no to mild disability). The PDDS range was selected to coincide with the EDSS 0–2 levels where previous research indicated limitations in the
ABILHAND’s measurement range and precision.
Patient Interviews
In Wave 1, concept elicitation interviews were used
to identify aspects of manual ability relevant to this
patient sample. This was to guide identification of
new items that could be used to supplement the
ABILHAND. We then asked patients to complete
the ABILHAND-56 to further assess its relevance
in early RRMS.
In Wave 2, we conducted cognitive debriefing interviews to establish relevance, clarity, and ease of completion of the draft supplementary items that were
generated in Wave 1. A “think aloud” process was
followed where patients were asked to complete the
items while thinking aloud and specifically noting any
queries, problems, or ambiguities of the questionnaire.23 All interviews were conducted over the telephone; the ABILHAND-56 and supplementary items
were displayed on patients’ computer screens and item
responses captured via an online platform. Interviews
were audio-taped and transcribed verbatim. In
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Figure 1. Study overview. EMS: Early Multiple Sclerosis; MS: multiple sclerosis; RRMS: relapsing–remitting multiple sclerosis.

addition, consultation interviews with three neurologists specializing in MS (SCohan, MDG, KKR) were
conducted at each of the two waves.
Materials
Based on the findings of our previous psychometric
analysis,20 an expanded four-level response scale,
very easy, easy, difficult, and impossible, was used
to improve the ABILHAND-56’s potential to capture manual disability in this early RRMS sample.9
Data Analysis
Qualitative analysis – concept elicitation.
Transcripts were analyzed thematically24 using
detailed line-by-line coding25 to examine, compare,
and develop treatment benefit conceptual domains
using ATLAS.ti software.26 Coding was targeted to
manual ability. Codes and quotations were inductively categorized into overarching domains that
reflected their conceptual underpinning. Each code
was compared with the rest of the data to create
analytical domains and sub-domains. Saturation
was assessed by ordering interviews chronologically,
then grouping these into quantiles and comparing
concepts emerging by each sequential quantile to
assess whether saturation had been reached (i.e., no
new concepts emerged).

www.sagepub.com/msjetc

Qualitative analysis – cognitive debriefing. This
analysis aimed to identify any potential wording
ambiguities and assess relevance and acceptability
in relation to each question item, response scale
and set of instructions as well as identify additional
items that could expand the measurement of manual
disability in early RRMS.23
Item generation. Item generation followed item
construction principles,13,27–29 aiming to have an
adequate range of items to cover the conceptual
breadth within each of the upper limb mobility
sub-domains. Concepts chosen for item development
were activities that were applicable to the broadest
range of people with MS. Lay language was used in
item constructions, using as many of the patients’
own words as possible while aiming for brevity
and minimal semantic overlap.
Quantitative data analysis. A small-scale RMT
analysis was performed on data available for the
ABILHAND-56 at Wave 1 and ABILHAND-56 as
well as supplementary items at Wave 2 using
RUMM2030 analytical software.30 RMT analysis
compares observed data against the stringent criteria
of the Rasch model, broadly aiming to assess the
sample-to-scale targeting, the measurement continuum, and sample measurement.31,32 Considering the
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small sample size, which would not permit any confirmatory conclusions to be made about the items’ measurement properties, the focus of this quantitative
analysis was to improve to scale targeting. Targeting
refers to the match between the distribution of a construct (e.g., manual disability) in the sample and the
range of the construct measured by a PRO instrument.33,34 The better this match is, the greater the
potential for accurate evaluation of a PRO instrument
and accurate person measurement. Results were interpreted with reference to published criteria wherever possible.32

Results
Study Sample
RRMS patients (n=88), with an RRMS diagnosis
<27 months, participated in Wave 1 interviews,

69.3% (n=61) of whom reported difficulties with
manual ability at screening (Table 1).
Wave 1 Qualitative Results
Concept elicitation. Eighty-two unique codes related to manual disability were identified. Seventy-five
of these emerged as “upper limb” concepts in initial
coding; seven additional upper limb concepts were
identified in retrospective review of activity limitation concepts. Inductive categorisation of these concepts into higher order sub-domains and domains
replicated the two-level manual disability conceptual
structure suggested in earlier work.20 Early RRMS
patients indicated issues with upper limb mobility
related to dexterity that were categorised under the
“fine motor” sub-domain as well as issues related to
strength categorized under the “power” sub-domain
(Table 2). Consultation with the three neurologists

Table 1. Sample characteristics.
Patient demographic and
clinical characteristics
PDSS score (n, %)
0 – normal
1 – mild disability
Age in years (meanSD)
Gender (n, %)
Male
Female
Race/ethnicity (n, %)
White
Asian
Black/African-American
Hispanic/Latino
Mixed race or “other”
Education (n, %)
High school
Some college/associate degree/
trade certification
Bachelor’s degree
Post-graduate degree
Employment status (n, %)
Full time
Part time
Not employed
Student
Homemaker

Wave 1 concept
elicitation sample
(n ¼ 88)

Wave 1 RMT
analysis sample
(n ¼ 29)

Wave 2 debriefing
and RMT sample
(n ¼ 30)

44 (50%)
44 (50%)
40.0 (8.72)

18 (62.1%)
11 (37.9%)
38.51 (7.66)

13 (43.3%)
17 (56.7%)
35.07 (8.11)

23 (26.1%)
65 (73.9%)

7 (24.1%)
22 (75.9%)

7 (23.3%)
23 (76.7%)

76
1
5
5
1

26
0
1
1
1

19
1
5
2
3

(86.4%)
(1.1%)
(5.7%)
(5.7%)
(1.1%)

(89.7%)
(0%)
(3.4%)
(3.4%)
(3.4%)

11 (12.5%)
28 (31.8%)

4 (13.8%)
7 (24.1%)

32 (36.4%)
17 (19.3%)

11 (37.9%)
7 (24.1%)

57
14
10
2
5

20
1
5
1
2

(64.8%)
(15.9%)
(11.4%)
(2.2%)
(5.7%)

(68.9%)
(3.4%)
(17.2%)
(3.4%)
(6.9%)

(63.3%)
(3.3%)
(16.7%)
(6.7%)
(10.0%)

2 (6.7%)
12 (40%)
7 (23.3%)
9 (30.0%)
22
5
2
1
0

(73.3%)
(16.7%)
(6.7%)
(3.3%)
(0.0%)

PDSS: Patient Determined Disease Steps; RMT: Rasch measurement theory; SD: standard deviation.
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Table 2. Examples of patient descriptions under fine motor and power sub-domains.
Upper limb mobility
sub-domain

Concept inductive code

Example quote

Fine motor

Brushing teeth

Fine motor

Computer: mouse use

Fine motor

Using keys

Power

Holding telephone

Power

Lifting things

Brushing one’s teeth – I would say very easy
right now, but when my hands are really
numb, it’s difficult. – BI-H-88
But when I work with the computer, I can’t use
the mouse with my right hand. My wrist just
gets an attitude, and it just goes wherever it
wants. So, I have to use my left hand. –
BI-H-55
There’s things like holding a key to put into a
keyhole can be challenging or even making
sure I have a good grip on my keys, so I don’t
drop them. – BI-W-28
Honestly, when I’m on my cell phone – you
know how you just lay on the couch with your
phone? I can’t (laughter) hold it up with my
left arm. I have to prop my arm up and look
at my phone. – BI-H-66
I wasn’t able to lift the boxes down, put them
back up. BI-H-02

specializing in MS was supportive of the twodomain structure.
Saturation analysis indicated that the 88 interviews
produced a comprehensive set of concepts with relation to manual disability in higher-functioning
people with RRMS; 66 of 75 of the initially identified upper limb mobility concepts arose within the
first 30 interviews and the remaining nine concepts
either echoed concepts derived from earlier interviews, were not generalizable to the entire MS population, or already existed in the ABILHAND-56.
Item generation. Of the identified concepts, 40 of 82
were not covered by existing ABILHAND items; of
these, neurologist feedback suggested that 20 of
these 40 were more clinically relevant to MS
patients with less severe manual disability. This
led to the drafting of 23 items: 11 “fine motor”
and 12 “power” items. We identified these item
sets as Early Multiple Sclerosis Manual Ability –
Fine Motor and Early Multiple Sclerosis Manual
Ability – Power.
Cognitive debriefing, item reduction and
refinement. Findings from Wave 2 interviews suggested that 20 of the 23 supplemental items were
well-understood and acceptable to patients.
However, three items appeared to overlap in

www.sagepub.com/msjetc

sub-domains. Patients interpreted “washing hair in
the shower” and “holding a full bag of groceries”
as relating to both lower limb and manual ability.
“Holding the steering wheel while driving for a long
time” was deemed unclear as patients associated this
item with multiple actions (including turning the
wheel and shifting gears). Subsequent consultation
with neurologists led to removal of the three items
not focused on manual ability and to wording revisions of the remaining supplementary items. For
example, “inserting a cable into a USB port” was
changed to the more widely-applicable task of
“inserting a cell phone charging cable into a
cell phone.”
Final supplementary items for ABILHAND in early
MS. Findings from Wave 2 supported a final item
pool comprising 10 “fine motor” and 10 “power”
Early Multiple Sclerosis Manual Ability items
(Table 3).
Quantitative Results: RMT Psychometric Analysis
In line with previous findings,20 endorsement frequencies indicated that none of the patients endorsed
the “impossible” response option for 49 of the 56
ABILHAND items in Wave 1 and 69 of the 79
ABILHAND plus supplemental items in Wave 2.
As this lack of endorsement of one of the four categories could artificially inflate the extent of
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Table 3. ABILHAND plus Early Multiple Sclerosis (MS) Manual Ability items, by theorized sub-scale.
ABILHAND 56-items
ABILHAND Fine Motor

ABILHAND Power

AB1
AB2
AB3
AB4
AB5
AB6
AB7
AB9
AB10
AB13
AB14
AB15
AB16
AB18
AB19
AB21
AB23
AB25
AB26
AB28
AB29
AB33
AB34
AB36
AB37
AB38
AB39
AB40
AB41
AB44
AB45
AB46
AB47
AB48
AB49
AB52
AB53
AB55
AB56

AB8
AB11
AB12
AB17
AB20
AB22
AB24
AB27
AB30
AB31
AB32
AB35
AB42
AB43
AB50
AB51
AB54

Turning over the pages of a book
Pulling up the zipper of trousers
Peeling onions
Sharpening a pencil manually
Using a spoon
Using a screwdriver
Picking-up a can
Filing one’s nails
Grasping a coin on a table
Peeling potatoes with a knife
Turning off a faucet
Buttoning up trousers
Dialing on a keypad phone
Cutting one’s nails
Turning on a radio
Turning on the switch of a lamp
Unwrapping a chocolate bar
Replacing a light bulb
Inserting a diskette into a drive
Spreading butter on bread
Counting paper money
Turning a key in a keyhole
Turning on a television set
Drawing
Ringing a door bell
Placing a glass on a table
Drinking a glass of water
Buttoning up a shirt
Threading a needle
Handling 4-color ballpoint pen
Blowing one’s nose
Wrapping up gifts
Fastening the zipper of a jacket
Fastening a snap
Writing a sentence
Opening mail
Typing
Taking a coin out of the pocket
Brushing one’s teeth

Taking the metallic cap off a bottle
Closing a door
Washing one’s face
Opening a screw-topped jar
Tearing open a bag of chips
Combing one’s hair
Hammering a nail
Making pancake batter
Washing one’s hands
Handling a stapler
Winding up a wrist watch
Brushing one’s hair
Cutting meat
Eating a sandwich
Shelling hazel nuts
Screwing a nut on
Squeezing toothpaste on
a toothbrush

Early MS Manual Ability items
Fine Motor

Power

FM01

Using a standard computer mouse

P01

FM02

Removing a credit card from slots/
pockets in a wallet

P02

Holding up a book or tablet
while reading
Holding a phone up to one’s ear for
a long time
(continued)
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Table 3. Continued
Early MS Manual Ability items
Fine Motor
FM03

Power
Removing a single piece of paper
from a file folder
Pushing buttons on a TV remote
control or similar device
Texting on a cell/mobile phone
Opening the metallic tab of a
soda can
Plugging an electrical plug into a
wall outlet that is easy to reach
Attaching a cell phone to a charging cable
Inserting a key into a keyhole
Accurately pouring liquids into a
measuring cup

FM04
FM05
FM06
FM07
FM08
FM09
FM10

P03

P08

Putting heavy items on a shelf
above head
Taking a heavy item down from a
shelf above head
Pulling the cap off a pen
Opening a safety cap on a medicine bottle
Lifting a full pot of water with one
handle off stove
Filling a kettle with water

P09
P10

Lifting a 20-lb weight one time
Blow drying one’s hair

P04
P05
P06
P07

Table 4. Overview of Rasch measurement theory (RMT) sample-to-scale targeting results.

ABILHAND scale version

Sample
measurement
rangea

Sample
measurement
mean (SD)a

Standard
error range

Sample
measurements %
beyond the
scale ceilingb

Wave
Wave
Wave
Wave
Wave
Wave
Wave
Wave
Wave
Wave
Wave
Wave

1.35–48.74
3.09–50.49
10.05–49.90
9.66–47.45
21.37–51.41
21.10–51.84
12.84–46.24
17.92–47.93
16.47–48.42
2.68–51.27
26.64–58.34
27.78–59.07

40.59
40.39
40.50
36.65
39.01
38.87
36.88
37.86
37.51
35.39
40.82
41.01

1.68–9.67
2.12–9.94
1.98–10.11
1.80–5.46
1.78–2.83
1.79–2.89
2.18–5.61
2.24–3.95
2.25–4.18
3.70–11.61
2.90–3.97
2.96–3.94

3.70%
7.49%
7.49%
20.00%
13.33%
13.33%
16.67%
13.33%
16.67%
23.33%
3.33%
0.00%

1
1
1
2
2
2
2
2
2
2
2
2

ABILHAND-56
Fine Motor-39
Power-17
ABILHAND-56
ABILHAND-56 þ draft items
ABILHAND-56 þ final itemsc
Fine motor-39
Fine motor–39 þ draft-items
Fine motor–39 þ final itemsc
Power-17
Power-17 þ draft items
Power-17 þ final itemsc

(8.98)
(9.34)
(7.77)
(10.95)
(7.75)
(7.92)
(10.64)
(9.18)
(9.76)
(12.72)
(6.85)
(6.64)

(n¼1)
(n¼2)
(n¼2)
(n¼6)
(n¼4)
(n¼4)
(n¼5)
(n¼4)
(n¼5)
(n¼7)
(n¼1)
(n¼0)

SD: standard deviation.
a
Where the scale item range is set to range from 0–100 and item mean always at 50; bpatients for whom the scale items
are too easy; cfinal items as available at Wave 2.

sub-optimal targeting for these analyses, the fourlevel response scale was rescored into three levels,
merging the two higher categories (“very easy” –
“easy” – “difficult/impossible”) for this analysis.
Table 4 details the sample-to-scale targeting for the
different scale versions at Wave 1 and Wave 2.
Findings are presented in an interval 0–100 transformed score, based on the interval logit metric

www.sagepub.com/msjetc

produced by RMT analysis. In alignment with the
sample’s PDSS scores, the sample mean was consistently below the scale mean (<50), indicating that
these patients lie on the lower end of the manual
disability continuum. The supplementary items
both in their draft and final form shift the sample
measurement means closer to the scale mean for all
three different versions of the scale (36.65 to 38.87,
36.88 to 37.51 and 35.39 to 41.01 for the
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ABILHAND,
respectively).

fine

motor,

and

power

scales

The range of standard error (SE) associated with
measurement is also reduced by the added supplementary items, indicating precision associated with
measurement is increased. The highest SE associated
with measurement is reduced from 5.46 to 2.89, 5.61
to 4.18 and 11.61 to 3.64 for the three respective
scales (Table 4). Finally, the percentage of people
at the ceiling (people for whom the scale items are
too easy) is reduced by the supplementary items for
the ABILHAND-56 and the Early MS Manual
Ability sub-scales. Figures 2–4 display the relative
improvements
to
sample-to-scale
targeting
graphically.
Discussion
In this multi-phase, mixed-methods psychometric
study, we identified 20 additional candidate items
to help improve the ABILHAND-56’s ability to
detect differences in manual ability in higher-functioning early RRMS patients. The robust development process included patient and clinician
feedback as well as modern psychometric analysis.
Wave 1 in-depth qualitative research findings indicated that the majority of existing ABILHAND-56
items were well-understood and appropriate to this

MS sample, confirming the ABILHANDs relevance
in this clinical population. In addition, we identified
a rich pool of relevant manual ability concepts aligning with the previously-identified two-level fine
motor and power manual ability conceptual framework.20 Clinical neurologists helped ensure that item
development focused on the most clinically relevant
additional supplementary items to expand the
ABILHAND’s measurement range. Wave 2 patient
interviews ensured relevance, understanding, and
acceptability of the supplementary items, in addition
to providing evidence for revision and refinement.
The macro-level psychometric analysis of the addition of the new items, based on RMT, suggests
improved targeting in this higher-functioning
RRMS sample, with lower ceiling effects and greater
precision (the ability to discriminate different levels
of manual ability). The analysis also provided evidence that an altered response scale to further
improve targeting for higher-functioning patients is
needed; this adaptation should therefore be considered for future MS studies using this scale.
A mixed method psychometric approach advances
our understanding of content validity and helps
ensure that a PRO instrument adequately reflects
the patient experience in a given context.13,14 This
process is vital to maximize clinical interpretability,
particularly when scores derived from PROs are

Figure 2. ABILHAND-56 sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original ABILHAND-56 items and (b) the improvements to the
match between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Manual Ability items.
Sample measurements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.
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Figure 3. Fine motor sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original Fine Motor 39 items and (b) the improvements to the
match between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Fine Motor items. Sample
measurements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.

Figure 4. Power sample to scale targeting.
The upper histograms represent the sample distribution, and the lower histograms the scale item threshold distribution plotted on the same interval
metric continuum of manual ability. (a) Displays sample-to-scale targeting of the original Power 17 items and (b) the improvements to the match
between sample and scale targeting introduced by merging the original with the Early Multiple Sclerosis (EMS): Power items. Sample measurements falling off the 0–100 range of the scale indicate patients for whom the scale remains too easy.

used to make decisions about the state of disease and
treatment.35 Our study used a novel mixed methods
approach that demonstrates how we can efficiently
conduct psychometric research to empirically troubleshoot legacy PRO instruments to ensure they
appropriately capture the targeted concept of interest
in a specific context of use.14
Traditionally, PRO instruments are developed via a
three-step approach moving through qualitative
concept elicitation and cognitive debriefing, to

www.sagepub.com/msjetc

quantitative field testing.36,37 However, we suggest
this standard linear methodology limits our ability to
efficiently construct items, elaborate upon response
options, identify anomalies, and troubleshoot overall
instrument design. Therefore, we advocate an integrated, iterative process, prior to PRO instrument
field testing. Using this approach, we generated optimal supplementary items for the ABILHAND in
MS, which could help improve the match between
manual ability in this population and subsequently
improve manual ability measurement and
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interpretation in MS studies. It is important that the
supplemental items only be used in conjunction with
the ABILHAND items, as they do not measure the
full spectrum of MS manual ability on their own.
The outcome of this study has been the development of
a potential new tool, which could be used in clinical
practice and clinical trials to measure changes in
manual ability in MS from the patients’ perspective.
Attention to manual ability should be a central focus in
clinical management and development of new therapeutic/clinical interventions, including emerging candidate reparative therapies.38 In the current MS
research and treatment landscape, it is increasingly
clear that measures need to be targeted to include the
highly-functioning population, and need to be sensitive
to changes relevant to their functional status, particularly in studies focusing on preserving physical ability
of newly diagnosed MS patients or reversing the
damage caused by the disease before irreversible
axonal loss takes place.19,20 Findings from this multiphase mixed methods study indicate that the Early MS
Manual Ability items expand manual ability measurement to issues relevant to higher-functioning patients
and therefore have the potential to increase sensitivity
to detect subtle clinical change in higher-functioning
MS patients. The recent treatment effects observed
with natalizumab on the 9HPT components of the primary endpoint in patients with advanced non-relapsing
secondary progressive multiple sclerosis (SPMS) in
the ASCEND natalizumab trial highlight the importance of having robust clinical outcome assessments,
including PROs, to measure treatment effects on upper
extremity function.39
While our findings with Early MS Manual Ability
are encouraging, they should be interpreted with
consideration of the study’s limitations. The structure of the ABILHAND and Early MS Manual
Ability item stem (“How difficult are the following
activities”) is simple and function descriptions are
brief; patients reported they were able to complete
the items quickly, with few problems. However,
given that the enhanced conceptual coverage in
higher-functioning people with MS is achieved by
adding 20 items to the existing ABILHAND-56, it
will be worthwhile to explore the burden presented
by adding additional items in future studies. Given
that inclusion criteria were based on self-report
information and because of the small sample size
of the RMT analysis, additional analysis in a larger
clinically defined sample would help confirm the
validity and generalizability of these findings. The
scoring structure of the ABILHAND-56 and Early
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MS Manual Ability items is empirically supported
by a psychometric analysis in one context and strictly requires further psychometric testing. Finally, the
revised scoring structure improves but does not
resolve all the measurement issues related to the
original ABILHAND-56.
Through mixed methods psychometric research, we
generated 20 supplementary items to improve the
targeting on ABILHAND-56 in higher-functioning
MS patients. The qualitative and quantitative findings support its use in measuring manual ability in
MS from the patients’ perspective. Further data from
a larger clinically defined sample is needed to confirm the new items’ measurement properties.
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